Skip to main content


Figure 2 | BMC Infectious Diseases

Figure 2

From: Hepatic profile analyses of tipranavir in Phase II and III clinical trials

Figure 2

Actions and outcomes of Grade 3/4 ALT/AST elevations among TPV/r recipients. TPV/r +LD patients = TPV/r patients co-infected with HBV/HCV or with baseline ALT/AST DAIDS >1. TPV/r -LD patients = TPV/r patients not co-infected with HBV/HCV and with baseline ALT/AST DAIDS ὄ1. +LD = patients with underlying liver disease (baseline evidence of active HBV/HCV infection or ALT/AST DAIDS >1); -LD = patients with no apparent liver disease (absence of active HBV/HCV infection and ALT/AST Grade ≤ 1); ALT = alanine aminotransferase; AST = aspartate aminotransferase; HBV = hepatitis B virus; HCV = hepatitis C virus; IQR = interquartile range; TPV/r = ritonavir-boosted tipranavir.

Back to article page